Sentiment Trading

Fujian Cosunter Pharmaceutical Co Ltd is poised for growth as the pharmaceutical sector experiences a surge in innovative drug approvals, driven by regulatory changes and market optimism.

Fujian Cosunter Pharmaceutical Co Ltd has seen a significant surge in market value and investor confidence following the approval of its innovative hepatitis B treatment, GST-HG141, for a Phase III clinical trial.

Fujian Cosunter Pharmaceutical Co Ltd faces challenges in sustaining growth and navigating market volatility, despite its significant contributions to the treatment of hepatitis B.